2 results match your criteria: "Shenzhen PKU-HKUST Medical Centre[Affiliation]"
Exp Ther Med
May 2024
Central Laboratory, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
Human induced pluripotent stem cells (hiPSCs) have been regarded as a potential stem cell source for cell therapy. However, the production of cells with mesenchymal potential from hiPSCs through spontaneous differentiation is time consuming and laborious. In the present study, the combined use of the GSK-3 inhibitor CHIR99021 and TGF-β was used to obtain mesenchymal stem cell (MSC)-like cells from hiPSCs.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
June 2013
Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Centre, Shenzhen, China.
The molecular mechanisms involved in the progression of clear cell renal cell carcinomas (ccRCCs) are still unclear. The aim of this study was to analyse the relationships between expression of RALYL and clinical characteristics. In 41 paired samples of ccRCCs and adjacent normal tissues, we used real-time qPCR to evaluate the expression of RALYL mRNA.
View Article and Find Full Text PDF